Safety and Immunological Response following heterologous prime-boost primary series and booster COVID-19 vaccination

Faculty of Medicine Siriraj Hospital0 个研究点目标入组 270 人开始时间: 2021年7月20日最近更新: 2024年8月19日

适应症

试验速览

暂无简介。

•1. Males or females at least 18 years of age (inclusive)
•2. Have not received COVID-19 vaccine or received 1st dose of COVID-19 vaccine (Inactivated vaccine or AstraZeneca) within 4 weeks
•3. Can understand Thai language through speaking, reading and writing
•4. Able to communicate through electronic tools such as Google form or line.
•5. Capable of attending all study visits according to the study schedule
•6. Capable of informed consent and provision of written informed consent before any study procedures

•1. Have history of severe drug or vaccine allergy (anaphylaxis)
•2. Have detected COVID-19 infection
•3. Have history of COVID-19 high risk contact
•4. Have received blood transfusion, plasma, blood product, blood components, immunoglobulins, antiviral or antibodies within the last 90 days
•5. Have history of cigarettes smoking, alcohol drinking and history of drug abuse
•6. Be pregnant
•7. Have unstable disease or could not control the symptom
•8. Have history of immunodeficiency or use immunosuppressant or steroid drugs
•9. Have any unusual symptoms or medical history that considered unable to participate in the study

发起方